Cassava Sciences Inc

NASDAQ:SAVAUnited States

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.

Contact Information

Headquarters

6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300AUSTIN, TX, United States 78731

Phone

512-501-2444

Fax

512-614-0414

Executives

Executive Chairman of the Board

Richard Barry

Chief Financial Officer

Eric Schoen

Senior Vice President, General Counsel

R. Christopher Cook

Chief Medical Officer

James Kupiec

Lead Independent Director

Sanford Robertson